Home › Non-Small Cell Lung Cancer › NCT05292521
Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer
Utilizing Patient Reported Quality of Life to Inform Patient Decision Making in Early-Stage Lung Cancer
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age \>= 18 years * Radiographic stage I-II non-small cell lung cancer (NSCLC) * Of note, separate tumor nodule(s) in an ipsilateral lobe different from that of the primary is considered T4 disease. However, these are treated as separate stage I or II lesions and will be eligible for this study. * Eligible for both surgery and SBRT * Able to provide informed consent in English * Have verbal fluency in English * Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure Exclusion Criteria: * Radiographic stage III-IV NSCLC except as noted above * Eligible for either only surgery or SBRT, but not both * Eligible for palliative-intent treatments or supportive care only. * Pregnant female participants. * Unwilling or unable to follow protocol requirements * Any condition which in the investigator's opinion deems the participant an unsuitable candidate * Cognitively impaired adults/adults with impaired decision-making capacity * Individuals who are not yet adults (infants, children, teenagers) * Prisoners
About the study
This clinical trial studies the effect of a quality of life intervention on decision-making in patients with early-stage lung cancer who are undergoing standard of care surgery or stereotactic body radiation therapy (SBRT). Providing quality of life outcome data to patients deciding between surgery and SBRT may help decrease decision regret and increase patient satisfaction with their care.
What is being tested
- Best Practice (other)
- Informational Intervention (other)
- Questionnaire Administration (other)
Sponsor: Roswell Park Cancer Institute · Participants: 150 · Started: Dec 21, 2023
Contact the study team
Official record on ClinicalTrials.gov — NCT05292521
Locations in the U.S.
| New York | Roswell Park Cancer Institute, Buffalo |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.